多发性骨髓瘤治疗压力后的克隆演化:异质性基因组异常与转录组趋同
研究对29例本机构多发性骨髓瘤患者及28例MMRF CoMMpass研究患者的配对肿瘤样本进行治疗前后基因组与转录组分析,发现46/57(82%)患者克隆组成发生变化,单核苷酸变异中位数从67增至86,晚期阶段E2F、MYC和糖酵解通路表达增加而TNF-NFkB和TGFbeta通路表达降低,显示疾病进展中支持增殖和代谢的通路转录组趋同。
要点
- 46/57(82%)患者治疗后克隆组成发生变化,单核苷酸变异中位数从67增至86。
- RAS基因异常率从60%升至72%,amp1q21从18%升至35%,TP53从9%升至18%。
- 晚期较早期E2F、MYC和糖酵解通路表达增加,TNF-NFkB和TGFbeta通路表达降低。
核心结论
- 研究显示多发性骨髓瘤疾病进展过程中存在支持增殖和代谢增加的通路转录组趋同。
研究设计与样本
- 研究纳入29例本机构多发性骨髓瘤患者和28例MMRF CoMMpass研究患者的配对肿瘤样本,比较治疗前后的基因组和转录组变化。
主要发现
- 46/57(82%)患者可检测到克隆组成变化,单核苷酸变异中位数从67增至86。
- 遗传异常 prevalence 增加最明显的是RAS基因(60%至72%)、amp1q21(18%至35%)和TP53(9%至18%)。
- 接受高剂量和低剂量美法仑的患者中均检测到SBS-MM1突变特征。
- 早期与晚期样本间共有2589个基因差异表达(FDR<0.05)。
- 基因集富集分析(GSEA)显示晚期较早期E2F、MYC和糖酵解通路表达增加,TNF-NFkB和TGFbeta通路表达降低;单样本GSEA(ssGSEA)评分显示这些变化在终末期疾病中最明显。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We investigated genomic and transcriptomic changes in paired tumor samples of 29 in-house multiple myeloma (MM) patients and 28 patients from the MMRF CoMMpass study before and after treatment. A change in clonal composition was found in 46/57 (82%) of patients, and single-nucleotide variants (SNVs) increased from median 67 to 86. The highest increase in prevalence of genetic aberrations was found in RAS genes (60% to 72%), amp1q21 (18% to 35%), and TP53 (9% to 18%). The SBS-MM1 mutation signature was detected both in patients receiving high and low dose melphalan. A total of 2589 genes were differentially expressed between early and late samples (FDR < 0.05). Gene set enrichment analysis (GSEA) showed increased expression of E2F, MYC, and glycolysis pathways and a decreased expression in TNF-NFkB and TGFbeta pathways in late compared to early stage. Single sample GSEA (ssGSEA) scores of differentially expressed pathways revealed that these changes were most evident in end-stage disease. Increased expression of several potentially targetable genes was found at late disease stages, including cancer-testis antigens, XPO1 and ABC transporters. Our study demonstrates a transcriptomic convergence of pathways supporting increased proliferation and metabolism during disease progression in MM.
引用
- Misund K, Hofste Op Bruinink D, Coward E, et al. Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence. Leukemia. 2022. PMID: 35643867. doi:10.1038/s41375-022-01597-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。